| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
INFLAMMATION/IMMUNITY/MEDIATORS
1Department of Surgery, Tufts-New England Medical Center and Tufts University School of Medicine, Boston; 2Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts; and 3Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania
Submitted 30 July 2004 ; accepted in final form 23 September 2004
Protease-activated receptor-2 (PAR-2) is a widely expressed tethered ligand receptor that can be activated by trypsin and other trypsin-like serine proteases. In the exocrine pancreas, PAR-2 activation modulates acinar cell secretion of digestive enzymes and duct cell ion channel function. During acute pancreatitis, digestive enzyme zymogens, including trypsinogen, are activated within the pancreas. We hypothesized that trypsin, acting via PAR-2, might regulate the severity of that disease, and to test this hypothesis, we examined the effect of either genetically deleting or pharmacologically activating PAR-2 on the severity of secretagogue-induced experimental pancreatitis. We found that experimental acute pancreatitis is more severe in PAR-2–/– than in wild-type mice and that in vivo activation of PAR-2, achieved by parenteral administration of the PAR-2-activating peptide SLIGRL-NH2, reduces the severity of pancreatitis. In the pancreas during the early stages of pancreatitis, the MAPK ERK1/2 is activated and translocated to the nucleus, but nuclear translocation is reduced by activation of PAR-2. Our findings indicate that PAR-2 exerts a protective effect on pancreatitis and that activation of PAR-2 ameliorates pancreatitis, possibly by inhibiting ERK1/2 translocation to the nucleus. Our observations suggest that PAR-2 activation may be of therapeutic value in the treatment and/or prevention of severe clinical pancreatitis, and they lead us to speculate that, from a teleological standpoint, PAR-2 may have evolved in the pancreas as a protective mechanism designed to dampen the injurious effects of intrapancreatic trypsinogen activation.
caerulein; mitogen-activated protein kinase; extracellular signal-regulated kinase 1/2
This article has been cited by other articles:
|
|
 |
|
  W. Namkung, J. S. Yoon, K. H. Kim, and M. G. Lee PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signaling Am J Physiol Gastrointest Liver Physiol, November 1, 2008; 295(5): G886 - G894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Laukkarinen, G. J D Van Acker, E. R Weiss, M. L Steer, and G. Perides A mouse model of acute biliary pancreatitis induced by retrograde pancreatic duct infusion of Na-taurocholate Gut, November 1, 2007; 56(11): 1590 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gorelick Pancreatic protease-activated receptors: friend and foe Gut, July 1, 2007; 56(7): 901 - 902. [Full Text] [PDF]
|
|
|
|
|
|
V. P Singh, L. Bhagat, S. Navina, R. Sharif, R. K Dawra, and A. K Saluja Protease-activated receptor-2 protects against pancreatitis by stimulating exocrine secretion Gut, July 1, 2007; 56(7): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. D. Van Acker, E. Weiss, M. L. Steer, and G. Perides Cause-effect relationships between zymogen activation and other early events in secretagogue-induced acute pancreatitis Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1738 - G1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sharma, X. Tao, A. Gopal, B. Ligon, M. L. Steer, and G. Perides Calcium dependence of proteinase-activated receptor 2 and cholecystokinin- mediated amylase secretion from pancreatic acini Am J Physiol Gastrointest Liver Physiol, October 1, 2005; 289(4): G686 - G695. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
